These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7526817)

  • 1. The measurement of fibrinogen in population-based research. Studies on instrumentation and methodology.
    Geffken DF; Keating FG; Kennedy MH; Cornell ES; Bovill EG; Tracy RP
    Arch Pathol Lab Med; 1994 Nov; 118(11):1106-9. PubMed ID: 7526817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring of hemostasis parameters during coronary thrombolysis with recombinant tissue-type plasminogen activator.
    Stump DC; Topol EJ; Chen AB; Hopkins A; Collen D
    Thromb Haemost; 1988 Apr; 59(2):133-7. PubMed ID: 2455358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of blood withdrawal and anticoagulant on clotting activity, hematologic data, and certain rheologic measurements.
    Reinhart WH; Haeberli A; Stark J; Straub PW
    J Lab Clin Med; 1990 Jan; 115(1):98-103. PubMed ID: 2105367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of EDTA samples for prothrombin time measurement in patients receiving oral anticoagulants.
    Horsti J
    Haematologica; 2001 Aug; 86(8):851-5. PubMed ID: 11522542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. D-Phe-Pro-Arg-chloromethylketone: its potential use in inhibiting the formation of in vitro artifacts in blood collected during tissue-type plasminogen activator thrombolytic therapy.
    Mohler MA; Refino CJ; Chen SA; Chen AB; Hotchkiss AJ
    Thromb Haemost; 1986 Oct; 56(2):160-4. PubMed ID: 2433785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of EDTA on routine and specialized coagulation testing and an easy method to distinguish EDTA-treated from citrated plasma samples.
    Crist RA; Gibbs K; Rodgers GM; Smock KJ
    Lab Hematol; 2009; 15(4):45-8. PubMed ID: 19923105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of specific antibody, D-Phe-Pro-Arg-CH2Cl and aprotinin for prevention of in vitro effects of recombinant tissue-type plasminogen activator on haemostasis parameters.
    Seifried E; Tanswell P
    Thromb Haemost; 1987 Oct; 58(3):921-6. PubMed ID: 2448890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the Q analyzer, a new cap-piercing fully automated coagulometer with clotting, chromogenic, and immunoturbidometric capability.
    Kitchen S; Woolley A
    Blood Coagul Fibrinolysis; 2013 Jan; 24(1):28-34. PubMed ID: 23249565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 96-well microfiltration assay for measurement of total clottable fibrinogen.
    Dempfle CE; Keller A; Argirion S; Heene DL
    Thromb Haemost; 1999 Feb; 81(2):264-7. PubMed ID: 10064004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of hemostatic factors in EDTA plasma.
    Green D; McMahon B; Foiles N; Tian L
    Am J Clin Pathol; 2008 Nov; 130(5):811-5. PubMed ID: 18854275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reproducibility and temporal stability of ADP-induced platelet aggregation: comparison of the anticoagulants sodium citrate and D-phenylalanyl-L-prolyl-L-arginyl-chloromethyl ketone.
    Horne WC; Anderson GM; Cohen DJ
    Am J Hematol; 1991 Sep; 38(1):48-53. PubMed ID: 1897514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the automated coagulation analyzer SYSMEX CA 6000.
    Quehenberger P; Kapiotis S; Handler S; Ruzicka K; Speiser W
    Thromb Res; 1999 Oct; 96(1):65-71. PubMed ID: 10554086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect on routine and special coagulation testing values of citrate anticoagulant adjustment in patients with high hematocrit values.
    Marlar RA; Potts RM; Marlar AA
    Am J Clin Pathol; 2006 Sep; 126(3):400-5. PubMed ID: 16880137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Complement activation in citrate plasma--inhibitory effect of anticoagulants on serum complement activation].
    Kobayashi E; Kitano E; Kondo H; Kitamura H
    Rinsho Byori; 1999 Feb; 47(2):160-4. PubMed ID: 10097633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can both EDTA and citrate plasma samples be used in measurements of fibrinogen and C-reactive protein concentrations?
    Skeppholm M; Wallén NH; Blombäck M; Kallner A
    Clin Chem Lab Med; 2008; 46(8):1175-9. PubMed ID: 18605954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Agglutination of rabbit platelets in plasma by the thrombin inhibitor D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone.
    Packham MA; Bryant NL; Guccione MA
    Thromb Haemost; 1990 Apr; 63(2):282-5. PubMed ID: 2363129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid evaluation of fibrinogen levels using the CG02N whole blood coagulation analyzer.
    Hayakawa M; Gando S; Ono Y; Mizugaki A; Katabami K; Maekawa K; Miyamoto D; Wada T; Yanagida Y; Sawamura A
    Semin Thromb Hemost; 2015 Apr; 41(3):267-71. PubMed ID: 25839869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. UPLC-ESI-QTOF/MS and multivariate data analysis for blood plasma and serum metabolomics: effect of experimental artefacts and anticoagulant.
    Barri T; Dragsted LO
    Anal Chim Acta; 2013 Mar; 768():118-28. PubMed ID: 23473258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of thrombin inhibitors ex vivo allows critical care clinical chemistry and hematology testing on common specimens.
    Lyon AW; Harding SR; Drobot D; Lyon ME
    Clin Biochem; 1997 Mar; 30(2):121-7. PubMed ID: 9127693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.
    Francart SJ; Hawes EM; Deal AM; Adcock DM; Gosselin R; Jeanneret C; Friedman KD; Moll S
    Thromb Haemost; 2014 Jun; 111(6):1133-40. PubMed ID: 24401946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.